Greenwich LifeSciences, Inc.

Equities

GLSI

US3968791083

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
19.94 USD -0.30% Intraday chart for Greenwich LifeSciences, Inc. +5.39% +89.54%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Greenwich Lifesciences Insider Bought Shares Worth $380,945, According to a Recent SEC Filing MT
Greenwich LifeSciences Secures Approval to Expand GLSI-100's Phase 3 Trial to Europe MT
Greenwich Lifesciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators CI
HC Wainwright Adjusts Greenwich LifeSciences Price Target to $36 From $38, Maintains Buy Rating MT
Greenwich LifeSciences, Inc. Provides Update on Phase III Clinical Trial, Flamingo-01 CI
Sector Update: Health Care Stocks Rise in Afternoon Trading MT
Greenwich LifeSciences Shares Surge on Planned Regulatory Filing of Breast Cancer Treatment MT
Greenwich LifeSciences Shares Rise as Company Prepares FDA Filing for Breast Cancer Immunotherapy DJ
Greenwich LifeSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Investors Await Powell's Jackson Hole Speech DJ
Greenwich LifeSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Greenwich LifeSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
North American Morning Briefing : Stocks to Extend -3- DJ
Greenwich Lifesciences, Inc. Confirms the Interest in Both of Itsgp2 Phase Iib Clinical Trial and Phase Iii Clinical Trial, Flamingo-01 CI
HC Wainwright Cuts Greenwich LifeSciences' Price Target to $38 From $78, Keeps Buy Rating MT
Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
North American Morning Briefing : Traders Await -3- DJ
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Focus on Bank -2- DJ
Greenwich LifeSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) dropped from S&P Global BMI Index CI
Greenwich LifeSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Greenwich LifeSciences Launches Late-Stage Breast Cancer Trial MT
Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial CI
Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial CI
Chart Greenwich LifeSciences, Inc.
More charts
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 will be delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. The Company's Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver certain immune system components to inhibit the spread of cancer.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
19.94 USD
Average target price
36 USD
Spread / Average Target
+80.54%
Consensus
  1. Stock
  2. Equities
  3. Stock Greenwich LifeSciences, Inc. - Nasdaq
  4. News Greenwich LifeSciences, Inc.
  5. Sector Update: Biotech Shares Helping Limit Declines by Health Care Stocks